Single cell RNA-seq identifies a FOS/JUN-related monocyte signature associated with clinical response of heart failure patients with mesenchymal stem cell therapy.

Hui Yuan, Pengfei Zhang, Yuanfeng Xin, Zhongmin Liu, Bingren Gao

Open access · hybridAbstract read

In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

0.7field-weighted citation impact, top 32% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

Machine learning approaches for biomarker discovery using single-cell RNA sequencing.Frontiers in bioinformatics · 2026
Review
Case report: Single-cell RNA sequencing of PBMCs highlights monocyte gene expression alterations in a type A HBV-ACLF patient.Heliyon · 2024
Article
From Cell to Gene: Deciphering the Mechanism of Heart Failure With Single-Cell Sequencing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hui YuanDepartment of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu, China.

Pengfei ZhangShanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Yuanfeng XinShanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.

Zhongmin LiuDepartment of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu, China.

Bingren GaoDepartment of Cardiac Surgery, Lanzhou University Second Hospital, Lanzhou 730030, Gansu, China.

Lanzhou University Second Hospital · CNShanghai East Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a serious global health issue that demands innovative treatment approaches. In this study, we collected samples from 4 HF patients before and after MSC therapy and performed scRNA-seq. After the MSC therapy, the proportion of CD14

Indexed as

Heart FailureMesenchymal Stem Cell TransplantationBiomarkersHumansMonocytesProto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junRNA-SeqBiomarkersFOS protein, humanJUN protein, humanProto-Oncogene Proteins c-fosProto-Oncogene Proteins c-junFOSheart failureJUNmachine learningMSCs

Identifiers

PMID38517374

DOI10.18632/aging.205670

PMCPMC11006470

OpenAlexW4393001822

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.